-
World Health Organization (WHO). (2021). Mental Health and Psychosocial Considerations During the COVID-19 Pandemic.
-
2022 State of Mental Health in America
-
Operation Deep Dive
-
Department of Veterans Affairs (VA). (2021). Suicide Data Report, 2020.
-
Centers for Disease Control and Prevention (CDC). (2021). Opioid Overdose.
-
The Drug Overdose Epidemic: Behind the Numbers
-
Johns Hopkins Medicine. (2021). Psychedelic Research.
-
MAPS (Multidisciplinary Association for Psychedelic Studies). (2021). Psychedelic-Assisted Therapies.
-
Beckley Foundation. (2021). Drug Policy Reform.
-
Drug Policy Alliance. (2021). Psychedelics.
-
David Nutt et al. (2010). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 376(9752), 1558-1565.
-
Drug Policy Alliance. (2021). Alcohol and Other Drugs.
-
National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2021). Alcohol's Effects on the Body.
-
Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565.
-
John Hopkins Study on Mystical Type Experiences for Normal Users
-
London Imperial College Therapeutic Potential of Psilocybin Past, Present, and Future
-
Psilocybin Produces Substantial & Sustained Decreases in Depression & Anxiety in Patients with Life-Threatening Cancer
-
Psilocybin for Treatment-Resistant depression: fMRI-measured brain mechanisms
-
Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with life-threatening Cancer
-
Psilocybin-Assisted Treatment for Alcohol Dependence: a proof-of-concept study
-
Adverse Experiences Resulting in Emergency Medical Treatment Seeking Following the use of Magic Mushrooms
-
The University of Alabama Study suggests psychedelic drugs could reduce criminal behavior
-
John Hopkins Study on Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
-
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735-40. doi: 10.4088/jcp.v67n1110. PMID: 17196053.
-
Smith, M. L., Ferris, J., & Staines, G. (2018). Acute safety and tolerability of psilocybin in healthy volunteers. The American Journal of Drug and Alcohol Abuse, 44(6), 668-676.
-
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.
-
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.
-
Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157-164.
-
Rosenbaum, C., Pynes, J., Oberlander, J., Levenson, J., Kuramoto, L., Halberstadt, A. L., ... & Clements, C. (2021). Safety and efficacy of psilocybin therapy for PTSD symptoms: A randomized controlled trial. Journal of Psychopharmacology.
-
Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoactive Drugs. 2021 Jan-Mar;53(1):85-95. doi: 10.1080/02791072.2020.1817639. Epub 2020 Sep 15. PMID: 32931403.
-
Bogenschutz, M. P., & Johnson, M. W. (2015). Psilocybin-assisted psychotherapy for PTSD. The Journal of Nervous and Mental Disease, 203(4), 271-281.
-
Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283
-
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., & MacLean, K. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621-632.